Parathormon, Kalzitonin, 25-Hydroxykalziferol und Knochenhistologie bei Patienten mit rheumatoider Polyarthritis*

Kokot, F; Kuska, J.; Białas, Brygida; Gburek, Z; Szczurek, Z; Śledziński, Zbigniew; Luciak, M

doi:10.1055/s-2008-1051059

Cited by 3 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As the mechanisms responsible for the altered base line hormone levels in uremic patients were discussed in detail in some of our previous original reports [9,[12][13][14][15] and review articles [11,19,20], this discussion will be confined only to the importance of opioid receptors in the pathogenesis of altered endocrine functions in ure mic patients. As can be judged from the literature, the role of opioid receptors in the pathogenesis of endocrine alterations in uremic patients has not been clarified.…”

Section: Discussionmentioning

confidence: 99%

Effects of Naloxone Administration on Endocrine Abnormalities in Chronic Renal Failure

Grzeszczak¹,

Kokot²,

Duława³

1987

Am J Nephrol

View full text Add to dashboard Cite

In 72 patients with end-stage renal failure and 70 healthy subjects, the influence of blockade of opioid receptors by naloxone on secretion of prolactin, lutropin (LH), follitropin (FSH), adrenocorticotropin (ACTH), somatotropin (HGH), insulin (IRI), glucagon (IR-G), parathyroid hormone (PTH) and calcitonin (CT) was studied. Administration of naloxone stimulated luliberin-induced LH and FSH secretion quantitatively equally in patients and controls. Blockade of opioid receptors was followed by a less marked suppression of chlorpromazine-induced prolactin secretion but by a higher response of hypoglycemia-induced ACTH secretion in uremic patients than in controls. In addition, a less marked suppressive effect of naloxone was noted on hypoglycemia-induced HGH secretion in chronic renal failure as compared with controls. Blockade of opioid receptors improved significantly glucose tolerance and glucose-induced insulin secretion in uremic patients and suppressed nearly completely glucagon secretion response during the second phase of a glucose tolerance test. Finally, administration of naloxone was followed by a blunted response of Ca-induced CT secretion and suppression of PTH. Data presented in this paper suggest the existence of hyperendorphinism in end-stage renal failure.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Naloxone Administration on Endocrine Abnormalities in Chronic Renal Failure

Grzeszczak¹,

Kokot²,

Duława³

1987

Am J Nephrol

View full text Add to dashboard Cite

show abstract

“…This finding may suggest a role of catecholamines in the pathogenesis of zona glomerulosa hypertrophy. 4 Although the Polish literature presents a description by Lityński 5 of 2 cases of patients with arterial hypertension in whom macronodular hypertrophy of the zona glomerulosa of 1 adrenal gland (in 1 deceased patient) or both adrenal glands (in the other deceased patient) was found, it is Conn 6 who is considered to have discovered PA because he proved that arterial hypertension in these patients was caused by aldosterone, a substance that was not assessed by Lityński in 1953. In accordance with the description by Conn in 1955 6 and reports by other authors in the subsequent years, PA was assumed to be a rare cause of moderate or mild arterial hypertension, responsive to pharmacological treatment. Hypokalemia and increased aldosteronuria (blood aldosterone levels were not yet estimated in the 1950s) as well as low plasma renin activity (PRA) were considered to be the leading diagnostic features of this clinical syndrome.…”

Section: Review Articlementioning

confidence: 99%

“…6,8,9 However, when the diagnostic criteria were developed to include also the renin activity test and numerous suppression or stimulation tests, aldosterone secretion tests, assessment of the aldosterone-renin ratio, levels of aldosterone and cortisol in the venous blood of the adrenal glands as well as modern imaging techniques of the adrenal glands, this rate has increased to 10% and more. 4,6,9,14,15 After much controversy, 10,13 scientists finally reached an agreement 13 that the prevalence of PA is from 5% to 15% among patients with arterial hypertension. According to Kaplan, 10 who is an expert It cannot be excluded that an aldosterone synthesis inhibitor, LCI699, will be a drug of choice in the treatment of PA in the near future.…”

mentioning

confidence: 99%

“…Thus, it is exceptionally difficult to determine the so called reference range for aldosteronemia and PRA. 4 Patients with PA constitute approximately 30% of all hypertensive patients, and 20% of the patients in this group have LRH with normal aldosteronemia and an increased A/PRA ratio. 5 Long-term therapy with low-dose aldosterone antagonists does not result in severe hyperkalemia even when patients are additionally treated with angiotensin-converting enzyme inhibitors or angiotensin type 1 receptor blockers, or exhibit a moderate reduction in estimated glomerular filtration rate.…”

Section: -3mentioning

confidence: 99%

See 1 more Smart Citation

Primary aldosteronism: a new insight into pathogenesis, diagnosis, and treatment in hypertensive patients

Hyla-Klekot¹,

Kokot²

2013

Polish Archives of Internal Medicine

View full text Add to dashboard Cite

Primary aldosteronism (PA) seems to be a pathogenetically heterogenous disease. It is suggested that approximately 30% of all hypertensive patients are affected by this disease. Autonomous hypersecretion of aldosterone, which is observed in this patient group, may be caused by an adrenal adenoma (aldosteronoma), hyperplasia of the zona glomerulosa, mutation of the KCNJ5 potassium channel, or other rare pathogenetic factors. Contrary to what was believed before, PA may be the cause of resistant hypertension rather than mild hypertension, while 70% of the patients have normal serum potassium levels rather than hypokalemia (previously believed to be a classical PA symptom). Hypertensive patients with normal or elevated aldosteronemia (A), suppressed plasma renin activity (PRA) and an elevated A/PRA ratio should undergo further diagnostic work-up for PA. PA is suspected to be the continuum of low-renin hypertension. First-choice therapy of PA should be based on long-term administration of low-dose mineralocorticoid receptor antagonists (spironolactone, eplerenone) and, in the nearest future, probably also aldosterone synthase antagonists such as CLI699, regardless of the morphological type of PA. It is still unknown whether pharmacological treatment will totally replace surgical treatment in some types of PA. Long-term administration of low-dose aldosterone antagonists is an effective and often underscored antihypertensive treatment, which rarely causes serious hyperkalemia if the kidney function is not impaired. KEy WoRdsdiagnosis, prevalence, primary aldosteronism, therapy

show abstract

Osteopenia in rheumatoid arthritis: a biochemical, hormonal and histomorphometric study

Rico

Hernández²,

Gómez-Castresana

et al. 1990

Clin Rheumatol

View full text Add to dashboard Cite

To determine whether the osteopenia of rheumatoid arthritis (RA) is due to reduction of trabecular bone mass (TBV) and/or cortical width (CW), we evaluated these parameters by bone histomorphometry; we also measured the calciotropic hormones parathormone(PTH) and calcitonin (CT), vitamin D [25(OH)D] and the biological markers of bone remodeling in a group of patients with RA. Study subjects were divided into Group C - premenopausal patients, and Group A - menopausal patients and men of the same ages. These groups were compared to two age-matched control groups, B and D. In both A vs. B and C vs. D, TBV and CW were significantly lower in patients. There were no differences in PTH or CT, but 25(OH)D was significantly reduced, and BGP, OHP/Cr and AP were raised in patients. Patients also exhibited TBV loss in more than 55% and CW loss in more than 98%. These changes suggest that the decline in bone mass, mainly cortical, but also trabecular, is due to increased bone turnover and enhanced resorption and seem to reflect intrinsic alterations of RA.

show abstract

Parathormon, Kalzitonin, 25-Hydroxykalziferol und Knochenhistologie bei Patienten mit rheumatoider Polyarthritis*

Cited by 3 publications

References 0 publications

Effects of Naloxone Administration on Endocrine Abnormalities in Chronic Renal Failure

Effects of Naloxone Administration on Endocrine Abnormalities in Chronic Renal Failure

Primary aldosteronism: a new insight into pathogenesis, diagnosis, and treatment in hypertensive patients

Osteopenia in rheumatoid arthritis: a biochemical, hormonal and histomorphometric study

Contact Info

Product

Resources

About